RESEARCH MONOGRAPH · KDC-MN-008

MOTS-c

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

72/100

Mitochondrial-derived peptide with real metabolic biology. One of the most interesting discoveries of the last decade

MOTS-c is the kind of compound that gets us excited because the discovery itself reframed what we thought we knew about mitochondrial biology. Pinchas Cohen's group at USC found it by mining the 12S rRNA region of the mitochondrial genome for open reading frames, and it turns out the mitochondrion has been encoding regulatory peptides this whole time. Thats not a minor finding, thats a real expansion of the mitochondrial-derived peptide (MDP) family alongside humanin and the SHLPs.

The biology is genuinely interesting. MOTS-c regulates metabolic homeostasis through AMPK activation in skeletal muscle, increases glucose disposal, and translocates to the nucleus under metabolic stress to regulate adaptive nuclear gene expression. The nuclear translocation finding is particularly striking because it positions MOTS-c as a mitonuclear retrograde signal, basically the mitochondrion telling the nucleus what to do under stress. The 2018 Cell Metabolism paper from the Cohen group on stress-induced nuclear translocation is the one to read first.

The human data is still early but growing. Aging-related decline in circulating MOTS-c is documented, and the K14Q polymorphism in Japanese populations is associated with metabolic outcomes. Exercise upregulates MOTS-c expression and treatment in mouse models partially mimics the metabolic effects of exercise (which is suggestive even if not yet a complete story).

Mechanism gets murkier downstream. The AMPK activation story is well supported. The nuclear binding partners are less clear. The receptor (if there is one) for extracellular MOTS-c hasn't been definitively pinned down.

Sourcing is reasonable. 16 residues, manageable synthesis, but watch the methionine residues for oxidation during long storage. Lyophilized at minus 80 is fine, repeated freeze-thaw will degrade. HPLC purity is achievable on any decent vendor. Slightly trickier than the shortest peptides on the market but not bad.

What we don't love is how this is starting to get picked up by the longevity-influencer crowd, which will inevitably distort the literature with marketing claims that outpace the actual evidence. The science is strong enough not to need exaggeration. It deserves real biochemistry, not vibes.

Genuinely promising. Watch the human trials currently in development.

Evidence: 60
Mechanism: 75
Reliability: 70
Safety: 78
Sourcing: 72
Value: 65
Signal: 78
Staying power: 80

Plain-language summary Intrigue 90 / 100

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, making it a unique mitochondrial-derived peptide. It activates AMPK, a master metabolic regulator linked to insulin sensitivity, fat oxidation, and exercise capacity. Research interest spans metabolic disease and longevity. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

16-residue mitochondrial-derived peptide, AMPK pathway modulator

A short open reading frame encoded within mitochondrial 12S rRNA, reported to modulate insulin sensitivity, exercise capacity, and metabolic homeostasis through AMPK-dependent mechanisms.

Abstract

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c; sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg; CAS 1627580-64-6; molecular formula C100H152N28O22S2; molecular weight 2174.59) is a 16-amino-acid peptide encoded within an open reading frame in the mitochondrial 12S ribosomal RNA gene MT-RNR1, first characterized in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California. It is the first short open reading frame (sORF) peptide identified in the mitochondrial genome, and its discovery has opened a substantial line of work on small mitochondrial-encoded peptides as endocrine and paracrine signals. Reported activities include enhanced insulin sensitivity in diet-induced and genetic obesity models, increased exercise capacity, improved glucose homeostasis through AMP-activated protein kinase (AMPK) activation, attenuated age-related insulin resistance, and effects on bone mineral density and immune function. Plasma MOTS-c levels decline with age in humans, which is the rationale for the geroprotective framing of the compound in research-grade vendor literature. The published preclinical literature is robust and has expanded steadily since 2015 with multiple independent laboratories contributing replication and extension studies. There is no FDA-approved IND for MOTS-c in any indication; preliminary Phase 1 work has been initiated by CohBar, Inc., the company that has licensed the platform from USC. The compound is not approved by any regulatory authority for human or veterinary use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-008

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

Acquire MOTS-c from the catalog

View MOTS-c →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

MOTS-c

Abstract

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Read the full monograph

Adjacent monographs